Keyword: Eli Lilly

Eli Lilly and Incyte’s second attempt to get U.S. approval of rheumatoid arthritis drug baricitinib could be scuppered again by lingering FDA concerns about safety.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.

The Terns deal is a poster child of "Lilly China Innovation and Partnerships," a new model in place of Lilly's Shanghai R&D center shuttered last September.

Eli Lilly is doubling down on novel mechanisms of action to steer clear of the “pile-on effect” seen in PD-1/PD-L1 and other hot targets.

Dominic Caruso retires as J&J's CFO, CVS hires ex-Lilly CFO Rice as the president of its PBM unit, former FDA informatics chief Kass-Hout joins Amazon.

The decision, which Alder described as mutual, leaves the biotech without a permanent leader in the runup to filing for approval of its migraine drug.

Andrew Witty will lead Optum as CEO, Novartis' operations lead André Wyss steps down, Gilead bids farewell to longtime R&D lead Norbert Bischofberger.

Anthera has cut loose its failed late-stage Lilly castoff Sollpura as it seeks “strategic alternatives.”

Memorial Sloan Kettering Cancer Center’s Maura Dickler, M.D., has been lined up as Lilly’s new VP of late-phase development in oncology.

The partnership for Aptose's third drug candidate comes as the biotech looks set to have its two lead drugs in clinical testing in the coming months.